Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
108.64+6.61 (+6.48%)
At close: 04:00PM EDT
108.04 -0.60 (-0.55%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Engulfing Line (Bullish)

Engulfing Line (Bullish)

Previous Close102.03
Open102.39
Bid106.47 x 800
Ask108.80 x 1300
Day's Range102.39 - 110.50
52 Week Range95.50 - 188.99
Volume1,188,918
Avg. Volume685,714
Market Cap26.049B
Beta (5Y Monthly)0.18
PE Ratio (TTM)5.34
EPS (TTM)20.34
Earnings DateNov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 02, 2022
1y Target Est161.41
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
21% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BNTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioNTech SE
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
  • Motley Fool

    Why Pfizer and BioNTech Stocks Zoomed Higher Today

    The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.

  • Motley Fool

    Why CureVac Stock Plunged Today

    Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.

  • CNW Group

    Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

    Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for ages 6 months and older. The updated vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age, the updated vaccine is authorized for administration as a thr

Advertisement
Advertisement